Should children as young as five be vaccinated with mRNA vaccines from Pfizer? The American pharmaceutical company’s CEO is upbeat that soon his company will open up this lucrative new market. After all, he reported recently that study data associated with kids aged five to 11 will be submitted to regulators before the end of the month. In March, TrialSite reported on a clinical program involving people as young as six months old. Now in ongoing promotional mode—probably not appropriate as none of these vaccines should be touted until regulators have reviewed the data—the CEO shared, “We know that the vaccine works very well in young kids,” informing news reporters yesterday. He emphasized that the company is “…working also to submit data from five to 11 [year old] this month.” Soon the age cohort two to five would be next; data for the age range of six months to two years old may be submitted by October or November.
TrialSite has reported on several trial sites conducting the Pfizer study. The Phase 2/3 clinical trial (NCT04816643) investigates the two-shot course with less dosage at ten micrograms compared to 30 micrograms for children and adults 12 and...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).